TNFA: TNF Pharmaceuticals, Inc. Price-to-Projected Revenue Ratio
The expected P/S chart for TNF Pharmaceuticals (TNFA) on GURU.Markets reflects valuation dynamics, where the metric has reached the level of . Quotes are driven by the success of anti-aging drug development, bypassing market cycles. However, external risks of raw material supply disruptions from Asia could slow growth. Meanwhile, management is effectively coordinating trials of unique molecules to combat inflammation.
Financial and market metric breakdowns for TNF Pharmaceuticals, Inc. (TNFA)
- stock price and consensus target price:
- market capitalization information:
- book value of equity indicators:
- company total debt and liquidity indicators:
Debt to Equity TNF Pharmaceuticals|TNFA - Long-Term Liabilities to Equity|Short-Term Debt to Capital TNF Pharmaceuticals|TNFA - Aggregate Debt Obligations|Debts to Book Capitalization TNF Pharmaceuticals|TNFA - Company Long-Term Debts|Company Short-Term Debt TNF Pharmaceuticals|Quick Liquidity tnfpharma.com
- financial results and valuation multiples details:
TNFA - Net Income|Projected Future Earnings TNF Pharmaceuticals|TNFA - P/E Multiple|Forward P/E Multiple TNF Pharmaceuticals|TNFA - Price/Earnings to Growth Multiple|EV/EBITDA Multiple TNF Pharmaceuticals, Inc.|TNFA - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months TNF Pharmaceuticals|TNFA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months tnfpharma.com|TNFA - Net earnings per one share growth for the current year|Earnings growth forecast for next year TNF Pharmaceuticals
- sales volume and revenue information:
Summary company analysis:TNF Pharmaceuticals TNFA
The reliability of an equity asset is determined by comparing market value with expected cash flows. The forward price-to-sales ratio measures business value per unit of future sales, which, given the R&D-oriented management of TNF Pharmaceuticals (TNFA), allows for an assessment of innovation investment efficiency by using the company's forward P/S valuation to identify whether the asset is overbought or undervalued relative to the industry context.
Competitors of TNF Pharmaceuticals
Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|eXoZymes (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX: Price to Expected Revenue Ratio|HYFT (ipatherapeutics.com) - Forward P/S Multiple|Forward P/S Multiple ABVC BioPharma|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals Inc. (CPIX)|QNTM (Quantum BioPharma Ltd.) - Forward Price to Sales|Forward P/S Multiple FGEN (fibrogen.com)|Telomir Pharmaceuticals (TELO) - Market Cap to Future Revenue Ratio|RANI - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Synergy CHC SNYR|RLYB: Forward P/S Multiple|Market Cap to Future Revenue Ratio Lexaria (LEXX)|Price-to-Projected Revenue Ratio Pulmatrix|Market Cap to Projected Revenue PTHL (ftzy.com.cn)|Forward P/S Multiple APM|Lyra Therapeutics, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple IBO (impactbiomedinc.com)|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP
